AGMB
AgomAb TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-17
Current thesis
Composite grade A from latest DB weights. Momentum 88.7 / Value 47.1
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -2.8.
What can break
Mixed signals. Wait for cleaner trend confirmation.
Momentum
89
Value
47
Sentiment
N/A
Setup hits (3d)
0 · Net Neutral
AI TargetsBase - · Bull - · Bear -
Data freshness
Prices
As of 2026-07-17
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-17 • Model: HYBRID_IC_RP
AI Memo
Unavailable: No memo yet
Investment thesisAs of 2026-07-17
Investment thesis
As of 2026-07-17
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $32.61
Why
Momentum89 · Δ7d -2.8
Value47 · Δ7d 0.0
SentimentN/A · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
89
40% active weight
Current posture
7d trendSoftening
Δ7d
-2.8
Δ21d
+64.4
Value
47
60% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Sentiment
N/A
Coverage pending
No current score
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 88.7 / Value 47.1
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$586.79M
Beta
-
Shares Out
48.74M
P/E (TTM) · Derived
-8.3
P/S (TTM)
-
P/FCF (TTM)
-
Rev YoY
-
EPS YoY
+61.8%
Gross Margin
-
Op Margin
-
Net Debt
-$135.37M
Current Ratio
6.49
As of 2026-07-17 • Updated nightlySource: Internal modelMethodology